Balance

Efficacy

Efficacy

Significant and sustained reduction in fasting triglycerides achieved with Waylivra1

When added to diet, Waylivra delivered a 77% mean reduction in fasting triglycerides at 3 months and maintained statically significant reductions for a full year.

†The Waylivra arm included patients who discontinued treatment after the 12-week primary endpoint period but returned for assessments over the 52-week study.

Waylivra reduces the risk of acute pancreatitis1

An analysis of patients with a history of recurrent pancreatitis events (≥ 2 events in the 5 years prior to Study Day 1) showed a significant reduction in pancreatitis attacks in Waylivra-treated patients compared to placebo treated patients (p=0.0242).1

In the Waylivra group, of the 7 patients who had 24 adjudicated pancreatitis attacks in the prior 5 years, none of the patients experienced a pancreatitis attack during the 52 week treatment period. In the placebo group, of the 4 patients who had 17 adjudicated pancreatitis attacks in the prior 5 years, 3 patients experienced 4 pancreatitis attacks during the 52-week treatment period.1

References

†The Waylivra arm included patients who discontinued treatment after the 12-week primary endpoint period but returned for assessments over the 52-week study.

  1. Waylivra® SmPC